Total medical devices industry venture financing deals in Q2 2020 worth $2.44bn were announced in the US, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 11.4% over the previous quarter and a rise of 24.9% when compared with the last four-quarter average of $1.96bn.
The US held a 53.2% share of the global medical devices industry venture financing deal value that totalled $4.59bn in Q2 2020.
In terms of deal activity, the US recorded 154 deals during Q2 2020, marking a drop of 9.4% over the previous quarter and a drop of 18.5% over the last four-quarter average.
The US medical devices industry venture financing deals in Q2 2020: Top deals
The top five medical devices industry venture financing deals accounted for 37.02% of the overall value during Q2 2020.
The combined value of the top five medical devices venture financing deals stood at $904m, against the overall value of $2.44bn recorded for the month.
The top five medical devices industry deals of Q2 2020 tracked by GlobalData were:
1) Canada Pension Plan Investment Board, Illumina and Public Sector Pension Investment Board’s $390m venture financing of Grail
2) The $194m venture financing of American Well by Allianz X and Takeda Pharmaceutical
3) Ally Bridge Group, Asahi Kasei Medical, Bain Capital Life Sciences, Endeavour Vision, Longitude Capital Management Co, Quaker Partners Management and Xeraya Capital Sdn’s $120m venture financing of Rapid Micro Biosystems
4) The $100m venture financing of Mindstrong by 8VC, Foresite Capital Management, General Catalyst Partners, Optum Ventures and What If Ventures
5) ACME Capital, Decheng Capital, Foresite Capital Management, Johnson & Johnson Innovation – JJDC and Madrone Capital Partners’ venture financing of Cue Health for $100m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.